Hysterectomy Technique Tied to Poorer Uterine Cancer Outcomes
MONDAY, Oct. 7, 2019 -- Uncontained power morcellation is associated with a higher mortality risk in women with occult uterine sarcoma, especially in those with occult leiomyosarcoma, according to a study published online Sept. 16 in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 7, 2019 Category: Pharmaceuticals Source Type: news
New insights into a rare type of cancer open novel avenues of study
(Karolinska Institutet) Undifferentiated uterine sarcoma is a very rare but extremely aggressive cancer type. It can be divided into four groups with different characteristics of clinical importance -- a new study at Karolinska Institutet in Sweden reveals. The results, published in the journal Clinical Cancer Research, also show that the survival rate of patients with a certain type of tumour is better than predicted. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 8, 2019 Category: Cancer & Oncology Source Type: news
Power morcellation: Questions linger for controversial tech
Dr. Amy Reed’s tragic case brought to light the cancer risks posed by power morcellation. Her death hasn’t stopped lingering questions about the technology. Power morcellators were used for 20 years to laparoscopically remove fibroids, benign tumors of the uterus, raising not a single adverse event report with the FDA. That all changed in 2013, when Dr. Amy Reed, an attending physician at Beth Israel Deaconess Medical Center, underwent a myomectomy using power morcellation at nearby Brigham & Women’s Hospital. Reed’s fibroids were not benign, but instead a malignant form of cancer called uterine sarcoma...
Source: Mass Device - June 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Gynecological Legal News News Well Recalls Regulatory/Compliance Surgical Cancer eximissurgical johnsonandjohnson powermorcellators Source Type: news
FDA Again Advises Against Morcellators for Fibroids FDA Again Advises Against Morcellators for Fibroids
The risk for uterine sarcoma being found in fibroids is too high, notes Dr Markman.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
10 Facts Women Should Know About Endometrial Cancer
The most common cancer of the reproductive organs in American women is endometrial cancer. The American Cancer Society estimates that for the year 2017, around 61,380 new cases of cancer of the body of the uterus will be diagnosed and about 10,920 women will die from cancers of the uterine body. These figures include both endometrial cancers and uterine sarcomas. Since endometrial cancer is a fairly common cancer in women, the more women know the facts about this disease, the greater their chance of knowing what symptoms to be aware of in order to have it diagnosed as early as possible, improving the likelihood of surviva...
Source: Healthy Living - The Huffington Post - June 5, 2017 Category: Consumer Health News Source Type: news
Uterine Sarcomas: The Latest Approaches for These Rare but Potentially Deadly Tumors
In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2017 Category: Cancer & Oncology Authors: Jing-Yi Chern, MD, ScM Leslie R. Boyd, MD Stephanie V. Blank, MD Tags: Gynecologic Cancers Oncology Journal Review Article Sarcoma Source Type: news
PI3K/mTOR inhibitors may be effective against some uterine sarcomas
The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 23, 2017 Category: Science Source Type: news
PI3K/mTOR inhibitors may be effective against some uterine sarcomas
(American Association for Cancer Research) The protein P-S6S240 may serve as an indicator of poor prognosis for patients with a hard-to-treat type of uterine sarcoma called leiomyosarcoma, and preclinical data suggest that patients whose tumors have this protein may respond to PI3K/mTOR inhibitors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2017 Category: Cancer & Oncology Source Type: news
GAO flags gaps in FDA ’ s adverse event system in power morcellator report
Limitations in the FDA’s adverse event reporting system for medical devices helped allow the widespread use of laparoscopic power morcellators for years before the risk that they can spread cancer became known, a government watchdog said this week. Medical device manufacturers and importers are required to tell the FDA about any device-related adverse events within 30 days. “FDA officials noted, however, the limitations in the current, passive, medical device reporting system, which relies on people to identify that a harm occurred or a risk is present, recognize that the harm or risk is associated with the ...
Source: Mass Device - February 10, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Wall Street Beat Women's Health Capitol Hill U.S. Government Accountability Office (GAO) Source Type: news
Gwen Ifill's Death Shows We Need Better Endometrial Cancer Research
Venerated journalist and anchor Gwen Ifill died Monday at the age of 61. The cause of death was endometrial cancer, with which she was diagnosed less than a year ago. Endometrial cancer has a reputation for being one of the most treatable and least-lethal gynecological cancers that women face. But as Ifill’s case shows, a significant minority of cases can be aggressive and fast-paced ― and they’re more likely to be concentrated among black women. For women who have recurrent endometrial cancer, doctors have few medications that can specifically target growth. “We don’t have as many too...
Source: Science - The Huffington Post - November 16, 2016 Category: Science Source Type: news
Olympus wins FDA nod & launches new power morcellator with tissue capture
Olympus (TYO:7733) said today it won FDA 510(k) clearance for its next-gen laparoscopic PK morcellator with tissue containment designed as a laparoscopic surgery option to avoid open hysterectomy and myomectomy for uterine fibroid removal The company’s newly launched morcellator includes the company’s PneumoLiner contained tissue extraction system. “Contained tissue extraction is continually evolving. As surgeons, it is our duty to evaluate potential solutions to the surgical challenges we face in clinical practice. We are pleased that Olympus has taken the initiative to develop a unique and well tested ...
Source: Mass Device - November 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Business/Financial News Food & Drug Administration (FDA) Regulatory/Compliance Women's Health Olympus Source Type: news
Power morcellation rates plunged after FDA warnings
Use of electric power morcellation for hysterectomy procedures has significantly declined after the FDA warned against the use of such devices in 2014, according to a new study. Data from the study was published this month in the Journal of the American Medical Association. The study examined a total of 203,520 women who underwent hysterectomy procedures from 2013 to the 1st quarter of 2015 as recorded in the Perspective database, which includes more than 500 hospitals in the U.S. Researchers found that the use of power morcellators peaked in the 4th quarter of 2013 at 13.7%, and dropped to only 2.8% by the 1st quarter of ...
Source: Mass Device - August 23, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Women's Health Source Type: news
ACS Report: Number of US Cancer Survivors Expected to Exceed 20 Million by 2026
By Stacy Simon A new report by the American Cancer Society – in collaboration with the National Cancer Institute – estimates there are more than 15.5 million cancer survivors alive in the US today, and that number will grow to more than 20 million by 2026. This includes everyone who’s ever had cancer, from the time of diagnosis for the rest of their life. The report, “Cancer Treatment & Survivorship Facts & Figures 2016-2017,” and an accompanying journal article in CA: A Cancer Journal for Clinicians were released June 2, 2016. The report says even though the rates of new cancer cases ...
Source: American Cancer Society :: News and Features - June 2, 2016 Category: Cancer & Oncology Tags: Coping with Cancer Breast Cancer Prostate Cancer Colon/Rectum Cancer Skin Cancer - Melanoma Source Type: news
Johnson & Johnson looks to settle morcellator lawsuits
Johnson & Johnson(NYSE:JNJ) is reportedly looking to settle 100s of product liability and wrongful death lawsuits brought over its now-recalled laparoscopic power morcellators used during surgeries to remove ostensibly benign uterine tumors. The morcellators, which use a cutting tip to shred and remove uterine tissue, have been implicated in the spread of a lethal cancer that can masquerade undetected as benign fibroids. The FDA in April 2014 issued a warning about the devices, later convening a special advisory panel to evaluate their continued use in the surgical suite. The watchdog agency estimates that about 0....
Source: Mass Device - March 21, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Legal News Product Liability Surgical Ethicon Inc. Johnson & Johnson Source Type: news